The Oncosearch | Oncotarget

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Research Paper

Norbert Vey, Lionel Karlin, Sophie Sadot-Lebouvier, Florence Broussais, Dominique Berton-Rigaud, JÃ©rÃ´me Rey, Aude Charbonnier, Delphine Marie, Pascale AndrÃ©, Carine Paturel, Robert Zerbib, Jaafar Bennouna, Gilles Salles, Anthony GonÃ§alves

Published Apr 3, 2018 · Vol. 9, No. 25 · pp. 17675-17688

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke Research Paper

Xingyang Yi, Jing Lin, Ju Zhou, Yanfeng Wang, Ruyue Huang, Chun Wang

Published Apr 3, 2018 · Vol. 9, No. 25 · pp. 17725-17734

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile Research Paper

Veronika Reidel, Johanna Kauschinger, Richard T. Hauch, Catharina MÃ¼ller-Thomas, Niroshan Nadarajah, Rainer Burgkart, Burkhard Schmidt, Dirk Hempel, Anne Jacob, Julia Slotta-Huspenina, Ulrike HÃ¶ckendorf, Christian Peschel, Wolfgang Kern, Torsten Haferlach, Katharina S. GÃ¶tze, Stefanie Jilg, Philipp J. Jost

Published Apr 3, 2018 · Vol. 9, No. 25 · pp. 17270-17281

Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer Research Paper

Agnieszka Dansonka-Mieszkowska, Lukasz M. Szafron, Joanna Moes-Sosnowska, Mariusz Kulinczak, Anna Balcerak, Bozena Konopka, Magdalena Kulesza, Agnieszka Budzilowska, Martyna Lukasik, Urszula Piekarska, Iwona K. Rzepecka, Joanna Parada, Renata Zub, Barbara Pienkowska-Grela, Radoslaw Madry, Jan K. Siwicki, Jolanta Kupryjanczyk

Published Apr 3, 2018 · Vol. 9, No. 25 · pp. 17735-17755

Results and adverse events of personalized peptide receptor radionuclide therapy with ⁹⁰Yttrium and ¹⁷⁷Lutetium in 1048 patients with neuroendocrine neoplasms Research Paper

Richard P. Baum, Harshad R. Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C. Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter HÃ¶rsch

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 16932-16950

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma Clinical Research Papers

Yoshiaki Yamamoto, Ryouichi Tsunedomi, Yusuke Fujita, Toru Otori, Mitsuyoshi Ohba, Yoshihisa Kawai, Hiroshi Hirata, Hiroaki Matsumoto, Jun Haginaka, Shigeo Suzuki, Rajvir Dahiya, Yoshihiko Hamamoto, Kenji Matsuyama, Shoichi Hazama, Hiroaki Nagano, Hideyasu Matsuyama

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 17160-17170

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer Research Paper

Cathy B. Moelans, Caroline M.G. van Maldegem, Elsken van der Wall, Paul J. van Diest

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 17078-17092

A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro Research Paper

Ken Okai, Naoki Ichikawa-Tomikawa, Akira C. Saito, Tetsuya Watabe, Kotaro Sugimoto, Daiki Fujita, Chikako Ono, Takasuke Fukuhara, Yoshiharu Matsuura, Hiromasa Ohira, Hideki Chiba

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 16588-16598

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events Case Report

Tatsuo Kanda, Shin Yasui, Masato Nakamura, Shingo Nakamoto, Koji Takahashi, Shuang Wu, Reina Sasaki, Yuki Haga, Sadahisa Ogasawara, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Yoshihiko Ooka, Eiichiro Suzuki, Tetsuhiro Chiba, Hitoshi Maruyama, Mitsuhiko Moriyama, Naoya Kato

Published Mar 23, 2018 · Vol. 9, No. 22 · pp. 16263-16270

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma Clinical Research Papers

Ling Li, Sa Xiao, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Yu Chang, Feifei Nan, Jiaqin Yan, Zhaoming Li, Mengyuan Shi, Ken H. Young, Mingzhi Zhang

Published Mar 23, 2018 · Vol. 9, No. 22 · pp. 16213-16219

Analysis of hematological parameters as prognostic markers for toxicity and survival of ²²³Radium treatment Research Paper

Asha Leisser, Marzieh Nejabat, Markus Hartenbach, Reza Agha Mohammadi Sareshgi, Shahrokh Shariat, Gero Kramer, Michael Krainer, Marcus Hacker, Alexander R. Haug

Published Mar 23, 2018 · Vol. 9, No. 22 · pp. 16197-16204

The CDK 4/6 inhibitor in HR-positive advanced breast cancer Review

Wu Ding, Zhian Li, Caiyun Wang, Guodong Ruan, Luping Chen, Chuanjian Tu

Published Mar 20, 2018

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study Research Paper

Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

Published Mar 20, 2018 · Vol. 9, No. 21 · pp. 15542-15551

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers Research Paper

Yasutaka Tono, Mikiya Ishihara, Yoshihiro Miyahara, Satoshi Tamaru, Hiroyasu Oda, Yoshiki Yamashita, Isao Tawara, Hiroaki Ikeda, Hiroshi Shiku, Toshiro Mizuno, Naoyuki Katayama

Published Mar 13, 2018 · Vol. 9, No. 19 · pp. 14909-14921

Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma Research Paper

Yuanyuan Zhang, Haixing Mai, Gang Guo, Guofang Bi, Guangtao Hao, Yuanyuan Li, Xiaofang Wang, Longmei Cheng, Jing Wang, Ruihua Dong, Zeyuan Liu, Lijun Chen, Hengyan Qu

Published Mar 6, 2018 · Vol. 9, No. 18 · pp. 14109-14123

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis Meta-Analysis

Shiqian Han, Yuanduo Hong, Tingting Liu, Na Wu, Zhijia Ye

Published Mar 6, 2018 · Vol. 9, No. 18 · pp. 14619-14629

Impact of physical exercise in cancer survivors during and after antineoplastic treatments Review

Martina Ferioli, Giorgio Zauli, Alberto M. Martelli, Marco Vitale, James A. McCubrey, Simona Ultimo, Silvano Capitani, Luca M. Neri

Published Feb 8, 2018 · Vol. 9, No. 17 · pp. 14005-14034

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis Research Paper

Tatsuo Kanda, Shin Yasui, Masato Nakamura, Shingo Nakamoto, Koji Takahashi, Shuang Wu, Reina Sasaki, Yuki Haga, Sadahisa Ogasawara, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Yoshihiko Ooka, Eiichiro Suzuki, Tetsuhiro Chiba, Hitoshi Maruyama, Fumio Imazeki, Mitsuhiko Moriyama, Naoya Kato

Published Feb 3, 2018 · Vol. 9, No. 14 · pp. 11631-11637

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer Research Paper

Katarzyna Morawska, FranÃ§oise Goirand, Laurine Marceau, Madeline Devaux, AdÃ¨le Cueff, AurÃ©lie Bertaut, Julie Vincent, Leila Bengrine-Lefevre, FranÃ§ois Ghiringhelli, Antonin Schmitt

Published Jan 30, 2018 · Vol. 9, No. 14 · pp. 11559-11571

Adverse effects of paternal chemotherapy exposure on the progeny brain: intergenerational chemobrain Research Paper

Anna Kovalchuk, Yaroslav Ilnytskyy, Rafal Woycicki, Rocio Rodriguez-Juarez, Gerlinde A.S. Metz, Olga Kovalchuk

Published Jan 23, 2018 · Vol. 9, No. 11 · pp. 10069-10082

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Research Paper

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke Research Paper

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile Research Paper

Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer Research Paper

Results and adverse events of personalized peptide receptor radionuclide therapy with ⁹⁰Yttrium and ¹⁷⁷Lutetium in 1048 patients with neuroendocrine neoplasms Research Paper

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma Clinical Research Papers

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer Research Paper

A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro Research Paper

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events Case Report

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma Clinical Research Papers

Analysis of hematological parameters as prognostic markers for toxicity and survival of ²²³Radium treatment Research Paper

The CDK 4/6 inhibitor in HR-positive advanced breast cancer Review

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study Research Paper

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers Research Paper

Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma Research Paper

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis Meta-Analysis

Impact of physical exercise in cancer survivors during and after antineoplastic treatments Review

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis Research Paper

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer Research Paper

Adverse effects of paternal chemotherapy exposure on the progeny brain: intergenerational chemobrain Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Research Paper

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke Research Paper

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile Research Paper

Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer Research Paper

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms Research Paper

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma Clinical Research Papers

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer Research Paper

A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro Research Paper

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events Case Report

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma Clinical Research Papers

Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment Research Paper

The CDK 4/6 inhibitor in HR-positive advanced breast cancer Review

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study Research Paper

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers Research Paper

Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma Research Paper

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis Meta-Analysis

Impact of physical exercise in cancer survivors during and after antineoplastic treatments Review

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis Research Paper

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer Research Paper

Adverse effects of paternal chemotherapy exposure on the progeny brain: intergenerational chemobrain Research Paper

Results and adverse events of personalized peptide receptor radionuclide therapy with ⁹⁰Yttrium and ¹⁷⁷Lutetium in 1048 patients with neuroendocrine neoplasms Research Paper

Analysis of hematological parameters as prognostic markers for toxicity and survival of ²²³Radium treatment Research Paper